ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 1925 • 2019 ACR/ARP Annual Meeting

    Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis

    Francesca Ridella 1, Giedre Januskeviciute 2, Chiara Trincianti 3, Evert Hendrik Pieter Van Dijkhuizen 4, Gabriella Giancane 5, Serena Pastore 6, Kirsten Minden 7, Maria Ekelund 8, Patrizia Barone 9, Matilda Laday 10, Nicolino Ruperto 11, Angelo Ravelli 12 and Alessandro Consolaro13, 1Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genova, Italy, 2Klaipeda Children's Hospital, Klaipeda, Lithuania, Klaipeda, Lithuania, 3Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, Genoa, Italy, 4Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, 5Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, 6Institute for Maternal and Child Health IRCCS "Burlo Garofolo," Trieste, Italy, Trieste, Italy, 7German Rheumatism Research Centre Berlin, and Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany, Berlin, Germany, 8Ryhov County Hospital, Futurum - the Academy for health and care, Jonkoping, Sweden, Jonkoping, Sweden, 9Department of Pediatrics, University of Catania, Catania, Italy, Catania, Italy, 10Spitalul Clinic Județean De Urgenta, Tîrgu-Mures, Romania, Tîrgu-Mures, Romania, 11Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 12IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 13Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy

    Background/Purpose: The assessment of disease activity plays a pivotal role in the management of children with juvenile idiopathic arthritis (JIA). Most recent recommendations require that…
  • Abstract Number: 2718 • 2019 ACR/ARP Annual Meeting

    A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis

    Kiana Taba1 and Elizabeth Ortiz 2, 1University of Southern California, LAGUNA HILLS, CA, 2LAC+USC/Keck Medicine of USC, Los Angeles

    Background/Purpose: The use of biologic DMARDs (bDMARDs) has vastly changed the treatment of autoimmune arthritis, both Rheumatoid Arthritis (RA) and polyarticular and oligoarticular Juvenile Idiopathic…
  • Abstract Number: 786 • 2019 ACR/ARP Annual Meeting

    Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis

    Jackeline Rodriguez-Smith1, Virginia Utz 2, Sherry Thornton 1, Grant Schulert 1, Adam Kauffman 3, Alyssa Sproles 1, Najima Mwase 1, Theresa Hennard 4, Alexei A. Grom 1, Mekibib Altaye 5, Gary Holland 6 and Sheila Angeles-Han 7, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Ophthalmology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Cincinnati Eye Institute and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 5Divison of Biostatistics and Epidemiology and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 6UCLA Stein Eye Institute and David Geffen School of Medicine at University of California, Los Angeles, Ca, Los Angeles, CA, 7Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Uveitis occurs in 10-20% of children with Juvenile Idiopathic Arthritis (JIA) and is typically asymptomatic. Ocular complications occur in 50% of children, (i.e. cataracts,…
  • Abstract Number: 2096 • 2019 ACR/ARP Annual Meeting

    An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients

    Valeria Valerio1, Maria Bazan 1, Mianbo Wang 2, Bruce Mazer 1, Elizabeth M. Hazel 3, Christian Pineau 4, Sasha Bernatsky 5, Brian Ward 6 and Ines Colmegna 6, 1The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5McGill University Health Center, Montreal, Canada, 6McGill University Health Center, Montreal, QC, Canada

    Background/Purpose: Annual vaccination with inactivated influenza vaccine is recommended for adults with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Despite this, influenza immunization coverage…
  • Abstract Number: 2724 • 2019 ACR/ARP Annual Meeting

    Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA

    Alexander Solyom1, Erik Sundberg 2, John Mitchell 3, Christina Grant 4, Carlos Ferreira 5, Paul Harmatz 6, Neslihan Mungan 7, Fatma Bulut 7, Christina Lampe 8, Andreas Hahn 8, Norberto Guelbert 9, Nur Arslan 10, Balahan Makay 10, Ratna Puri 11, Sunita Bijarnia-Mahay 11, Laila Selim 12, Iman Gamal el Din 12, Seema Kapoor 13, Maja DiRocco 14, Seza Ozen 15, Ezgi Batu 15, Gulden Gokcay 16, Marta Torcoletti 17, Alan Kimura 18 and Bo Magnusson 2, 1Enzyvant, Basel, Switzerland, 2Karolinska University Hospital, Stockholm, Sweden, 3Montreal Children's Hospital, Montreal, Canada, 4Children's National Medical Center, Washingotn, DC, 5Children's National Medical Center, Washington, DC, 6UCSF Benioff Children's Hospital Oakland, Oakland, CA, 7Cukurova University Hospital, Adana, Turkey, 8University Hospital Giessen, Giessen, Germany, 9Children's Hospital of Cordoba, Cordoba, Argentina, 10Dokuz Eylul University Hospital, Izmir, Turkey, 11Sir Ganga Ram Hospital, Delhi, India, 12Cairo University Children's Hospital, Cairo, Egypt, 1313Lok Nayak Hospital and Maulana Azad Medical College, Delhi, India, 14Istituto Giannina Gaslini, Genoa, Italy, 15Hacettepe University Hospital, Ankara, Turkey, 16Istanbul University, Istanbul, Turkey, 17University of Milan, Milan, Italy, 18Enzyvant, Cambridge, MA

    Background/Purpose: The cardinal clinical symptoms of Farber disease (arthritis/contractures, subcutaneous granulomatous nodules, dysphonia) may be misdiagnosed as JIA. Mutations in the ASAH1 gene and the…
  • Abstract Number: 2703 • 2019 ACR/ARP Annual Meeting

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices

    Sarah Ringold 1, George Tomlinson 2, Pamela Weiss 3, Laura Schanberg 4, Mary Ellen Riordan 5, Anne Dennos 6, Vincent Del Gaizo 7, Katherine Murphy 8, Brian Feldman 9 and Yukiko Kimura10, 1Seattle Children's, Seattle, 2University of Toronto, Toronto, ON, Canada, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Duke University Medical Center, Durham, NC, 5Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, NJ, 6Duke Clinical Research Institute, Durham, NC, 7Childhood Arthritis & Rheumatology Research Alliance, Whitehouse Station, NJ, 8Louisiana Office of Public Health, New Orleans, LA, 9University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada, 10Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH

    Background/Purpose: There continues to be uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance…
  • Abstract Number: 787 • 2019 ACR/ARP Annual Meeting

    Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis

    Mia Glerup1, Steffen Thiel 2, Veronika Rypdal 3, Ellen Dalen Arnstadt 4, Maria Ekelund 5, Suvi Peltoniemi 6, Kristiina Aalto 6, Marite Rygg 7, Susan Nielsen 8, Anders Fasth 9, Lillemor Berntson 10, Ellen Nordal 3 and Troels Herlin 11, 1Dept of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Biomedicine, Aarhus University, Aarhus, Denmark, Aarhus, Denmark, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Trondheim, Norway, 5Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden. Department of Pediatrics, Ryhov County Hospital, Jonkoping, Sweden., Jonkoping, Sweden, 6Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 7Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Tromsø, Norway, 8Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhavn, Denmark, 9Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 10Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 11Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus, Denmark

    Background/Purpose: There is an increasing body of evidence that inadequately controlled activation of complement factors leading to either overactivity or deficiency may be involved in…
  • Abstract Number: 2258 • 2019 ACR/ARP Annual Meeting

    Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis

    Sandra Pelaez 1, Vincent Gosselin Boucher 2, Valeria Valerio 3, Elizabeth M. Hazel 4, Kim Lavoie 5, Brian Ward 6 and Ines Colmegna6, 1Research Centre of the Sainte-Justine University Hospital, Montreal, Canada, 2Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, Canada, 5Montreal Behavioural Medicine Centre, Centre Intégré Universitaire de santé et services sociaux du Nord-de-l’Ile-de-Montréal (CIUSSS-NIM), Hôpital du Sacré-Cœur de Montréal & Department of Psychology, Université du Québec à Montréal, Montreal, Canada, 6McGill University Health Center, Montreal, QC, Canada

    Background/Purpose: Vaccine hesitancy -the reluctance or refusal to vaccinate despite the availability of vaccines- is one of the threats to global health set by the…
  • Abstract Number: 790 • 2019 ACR/ARP Annual Meeting

    Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?

    Ovgu Kul Cinar1, Charlene Foley 2, Ali Al-Hussain 3, Kimberly Gilmour 4, Matthew Buckland 4 and Muthana Al-Obaidi 5, 1Great Ormond Street Hospital, Lonodn, United Kingdom, 2Great Ormond Street Hospital, London, Ireland, 3Great Ormond Street Hospital, London, United Kingdom, 4Great Ormond Street Hospital NHS Trust, Camelia Botnar Laboratories, London, United Kingdom, 5Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Antinuclear antibodies (ANA) are autoantibodies that recognise cellular antigens found predominantly in the cell nucleus. They are associated with numerous autoimmune diseases such as…
  • Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting

    Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis

    Ekaterina Alexeeva1, Rina Denisova 2, Tatyana Dvoryakovskaya 2, Ksenia Isaeva 2, Ivan Kriulin 2, Alina Alshevskaya 3 and Andrey Moskalev 3, 1National Medical Research Center of Children`s Health, Moscow, Russia, 2NMRCCH, Moscow, Russia, 3Biostatistics and Clinical Trials Center, Novosibirsk, Russia

    Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
  • Abstract Number: 804 • 2019 ACR/ARP Annual Meeting

    STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis

    Jose Luis Tandaipan1, Mireia Lopez Corbeto 2 and Estefania Moreno Ruzafa 3, 1Hospital Universitari Mutua Terrassa, Terrassa, Spain, 2Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, 3Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Gain-of-function mutations in TMEM173 encoding STING (Stimulator of Interferon Genes) underlie a novel type I INF termed SAVI syndrome. It is characterized by a…
  • Abstract Number: 2699 • 2019 ACR/ARP Annual Meeting

    Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

    Najima Mwase 1, Theresa Hennard 2, Joseph McDonald 3, Amy Cassedy 4, Onengiya Harry 3 and Sheila Angeles-Han5, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, 4Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cinicinnati

    Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, leading to ocular complications and blindness when not adequately treated. First…
  • Abstract Number: 1849 • 2018 ACR/ARHP Annual Meeting

    Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort

    Mia Glerup1, Veronika Rypdal2,3, Ellen Dalen Arnstad4,5, Maria Ekelund6,7, Suvi Peltoniemi8, Kristiina Aalto8, Marite Rygg9,10, Peter Toftedal11, Susan Nielsen11, Anders Fasth12, Lillemor Berntson13, Ellen Nordal14,15 and Troels Herlin16, 1Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Denmark, Aarhus, Denmark, 2Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, 3Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, 4Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, 5Dept. of Pediatrics, Levanger Hospital, Nord-Trøndelag, Norway, Trondheim, Norway, 6Department of Pediatrics, Dept. of Pediatrics, Ryhov County Hospital, Jonkoping, Sweden, Jonkoping, Sweden, 7Uppsala University, Uppsala, Sweden, Jonkobing, Sweden, 8Hospital for Children and Adolescents, University of Helsinki, Finland, Helsinki, Finland, 9Dep. Clin. and Mol. Med., Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, 10Department of Pediatrics, Dept. of Pediatrics, St. Olavs Hospital, Norway, Trondheim, Norway, 11Department of Pediatrics, Dept. of Pediatrics, Copenhagen University Hospital, Denmark, Copenhagen, Denmark, 12Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, 13Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 14Departments of Pediatrics, Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, 15Department of Clinical Medicine, Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, 16Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark

    Background/Purpose: Innovative changes towards targeted treatment have improved the outcome dramatically for juvenile idiopathic arthritis (JIA) but the question remains how well these patients perform…
  • Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting

    New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients

    Alessandro Consolaro1,2, Chiara Trincianti1, Pieter van Dijkhuizen3, Giedre Januskeviciute4, Gabriella Giancane5, Alessandra Alongi1, Joost Swart3, Nicola Ruperto6,7 and Angelo Ravelli2,8, 1University of Genova, Genova, Italy, 2Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, 3UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, 4Istituto Giannina Gaslini, Genova, Italy, 5Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, 6Universita di Genova Pediatria II, Genova, Italy, 7Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 8University of Genova, Genoa, Italy

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
  • Abstract Number: 2017 • 2018 ACR/ARHP Annual Meeting

    Oral Microbiota in New-Onset Juvenile Idiopathic Arthritis

    Albert Chow1,2,3, Sriharsha Grevich1,2,3, Peggy Lee4, Jeffrey McLean4, Sarah Ringold1,3,5, Roger Bumgarner6 and Anne Stevens1,2,3, 1Pediatrics, University of Washington, Seattle, WA, 2Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, 3Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, 4Dentistry, University of Washington, Seattle, WA, 5Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, 6Microbiology, University of Washington, Seattle, WA

    Background/Purpose: Oral microbial dysbiosis of specific organisms such as Porphyromonas, Aggregatibacter, Tannerella, and Treponema in dental plaque has been implicated in the pathogenesis of adult…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology